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Abstract. Thrombospondin-related adhesive protein (TRAP) of Plasmodium falciparum is currently being tested in
human vaccine studies. However, its natural reactivity in the field remains poorly characterized. More than 40% of 217
Kenyan donors responded in an ex vivo interferon- (IFN-) enzyme-linked immunospot (ELISPOT) assay to at least
one of 14 20mer peptides spanning 42% of the antigen. Reactivity was comparable from early childhood (>1 year of age)
to old age, and the maximal precursor frequency of TRAP-specific cells to all 14 peptides was 1 in 4,000. Prospective
follow-up for one year indicated that these low-level ex vivo responses to TRAP did not protect against the subsequent
development of malaria. Retesting of selected donors after one year showed a complete change in the reactivity pattern,
suggesting that malaria-specific ex vivo IFN- ELISPOT assay responses are short lived in naturally exposed donors,
even to conserved epitopes. This study provides important information regarding natural reactivity to a key malaria
antigen.
INTRODUCTION
The development of an effective vaccine may provide the
most effective method of reducing the worldwide burden of
malaria. Understanding the mechanisms of natural protective
immunity, and identifying target antigens and epitopes, are
important for effective vaccine development. Controversy re-
mains over whether protective effector mechanisms and an-
tigens identified in animal studies, or vaccine induced protec-
tive responses, can predict protective mechanisms induced by
natural malaria infection. Despite strong laboratory evidence
that pre-erythrocytic protection is T cell mediated, few field
studies have directly looked for correlates of protection with
T cell responses in malaria exposed populations. Those to
date have assessed lymphoproliferative responses to malaria
derived peptides and proteins and cytokine release by an en-
zyme-linked immunosorbent assay (ELISA),1−6 yet none
have convincingly demonstrated a protective T cell response.
Numerous studies implicate the Th1 type cytokine inter-
feron- (IFN-) as the effector mechanism by which T cells
mediate protection at the pre-erythrocytic stage of malaria
infection.7−9 The enzyme-linked immunospot (ELISPOT) as-
say detects individual T cells present in peripheral blood that
release IFN- within 16 hours of stimulation with specific
antigen. It thus provides an immediate reflection of the pre-
cursor frequencies of peptide-specific IFN-−producing cells
in peripheral blood without prolonged selective cultures, such
as the ones necessary for limiting dilution analysis. The
ELISPOT assay is simple to perform and provides a highly
sensitive method for assessing cytokine production in malaria
exposed populations.10−13 In animal studies of pre-erythrocyt-
ic vaccines IFN- ELISPOT assay responses to pre-erythro-
cytic antigens of more than a few hundred per million sple-
nocytes are strongly associated with protection.14,15 The hu-
man RTS,S vaccine, which is based on the pre-erythrocytic
antigen circumsporozoite (CS) protein, protects malaria-
naive donors against homologous challenge.16 Those pro-
tected had detectable but modest levels of CS protein-specific
IFN-−producing CD4+ T cells by ELISPOT assay and high
levels of antibody to CS. However, it is not known if IFN-
−producing T cells detected by ELISPOT assay in vacci-
nated or naturally exposed humans directly mediate protec-
tion.
A favored pre-erythrocytic vaccine candidate antigen is
thrombospondin-related adhesive protein (TRAP),17 also re-
ferred to as SSP2.18 This protein is located in the secretory
organelles of sporozoites and is released onto the sporozoite
surface upon contact with target cells.19 It is responsible for
the gliding motility of sporozoites,20 and is involved in hepa-
tocyte invasion.21 Adoptive transfer experiments have dem-
onstrated protective TRAP-specific CD8+ T cells in mice.22
Immunization with a mixture of transfected cells expressing
Plasmodium yoelii TRAP/SSP2 and CS protected mice
against this parasite.23 A DNA/modified virus Ankara
(MVA) prime-boost regimen using the P. berghei TRAP an-
tigen gave very substantial protection in mice.14 Immuniza-
tion with a linear synthetic peptide containing four copies of
a P. yoelii TRAP/SSP2 sequence induced CD4+ T cell and
IFN--dependent sterile protective immunity against malaria
challenge in AJ mice, but not BALB/c or C57BL/6 mice.24
TRAP-specific CD8+ T cells have been demonstrated in
sporozoite immunized and naturally exposed humans,25−27
and TRAP-specific CD4+ T cell reactivity has been detected
in naturally exposed Gambians.10 Two field studies support a
protective role for humeral responses to TRAP in naturally
exposed humans,28,29 but no human studies have assessed
protective TRAP-specific CD4+ or CD8+ T cells.
The present study was undertaken to determine whether
naturally exposed Kenyans have P. falciparum TRAP-specific
IFN--producing T cell responses, and compare ELISPOT
assay reactivity between adults and children in terms of re-
sponder numbers, precursor frequency levels, and the reper-
toire of peptide responses. Peptides spanning 240 amino acid
residues of TRAP strain NF54 (42% of the antigen) were
tested in overnight ELISPOT assays for their ability to induce
IFN- production in over 200 Kenyan volunteers between 1
month and 81 years of age. These donors were then followed
up weekly for one year for episodes of clinical malaria and the
protective value of the ELISPOT assay responses was ana-
lyzed. Selected donors were retested after one year in iden-
tical assays to determine the long-term stability of these re-
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sponses. This data provides a comprehensive picture of natu-
ral T cell reactivity to TRAP in a naturally exposed popula-
tion.
MATERIALS AND METHODS
Study site and volunteers. Two hundred seventeen donors
between 1 month and 81 years of age (57% females, 43%
males) were recruited from Ngerenya in the northern part of
Kilifi District in coastal Kenya. Informed consent was ob-
tained from all donors or the parent/guardian of children.
Five milliliters venous blood was collected from each donor at
Kilifi District Hospital throughout the first two weeks of Sep-
tember, at the end of the peak malaria transmission period
(June to August).30 Ngerenya district is an area of moderate
malaria transmission with an entomologic inoculation rate of
10 (range 3−15) infectious bites per person/year (Mbogo C,
unpublished data). Fifteen malaria-naive adult employees at
the John Radcliffe Hospital in Oxford were also recruited
into the study as controls. Ethical approval for this study was
obtained from the Kenyan Ethical Committee, and is pub-
lished with the permission of the director of the Kenya Medi-
cal Research Institute.
Preparation of peripheral blood mononuclear cells
(PBMCs). Peripheral blood mononuclear cells were isolated
by density gradient centrifugation on Lymphoprep (Ny-
comed, Oslo, Norway), collected from the interface, washed
three times in RPMI 1640 medium, and resuspended in com-
plete RN5 medium (RPMI 1640 medium supplemented with
5% heat-inactivated human AB serum, 2 mM glutamine,
100 g/ml of streptomycin, and 100 units/ml of penicillin) for
use in cellular assays. The CD4+ and CD8+ T cell depletions
were performed using anti-human CD4 and CD8 magnetic
dynabeads, respectively, (Dynal, Bromborough, United King-
dom) according to the manufacturer’s instructions. The pro-
tocol reliably depleted >95% of the CD4+ or CD8+ cells as
confirmed by fluorescent-activated cell sorting analysis
(FACScan analysis). Cells were recounted and resuspended
in RN5 medium for use in cellular assays.
Peptides.A pilot study of 65 Kenyan adults was performed
to select the peptides for the trial. A panel of 53 overlapping
20mer peptides spanning the length of P. falciparum TRAP
were tested in ex vivo IFN- ELISPOT assays in the 65 do-
nors. Fourteen TRAP 20mer peptides (denoted tps) from
strain NF54 were selected for the study. Those selected in-
cluded all those that induced reactivity in 9% of the 65
donors plus a few of particular interest, such as one highly
conserved (tp23), one highly polymorphic (tp43), or one con-
taining a domain of proposed functional significance (tp30)
(Table 1). Peptides were reconstituted in phosphate-buffered
saline (PBS) (Sigma, Dorset, United Kingdom) and PBS
alone was used as a negative control. Overlapping peptides
tp4, tp5, and tp6 were pooled and tested as one group, as were
peptides tp30 with tp31 and tp37 with tp38. This gave 10 P.
falciparum TRAP conditions for testing in the donors (Table
1). None of the selected peptides induced IFN- ELISPOT
assay responses in 15 naive control donors tested under iden-
tical conditions in Oxford. Two peptides contained TRAP
sequences conserved across all known antigenic variants
worldwide (tp2 and tp23), and six peptides were conserved
across all known African variants (tp2, tp6, tp14, tp23, tp40,
and tp51) (Table 1). The CD4+ and CD8+ cell depletion stud-
ies suggested that IFN- ELISPOT assay responses to seven
of the 14 TRAP peptides elicited CD4+ T cell responses, and
two were CD4+ or CD8+ T cell mediated even in the same
donor (summarized in Table 1). All peptides were used at a
final concentration of 25 g/mL following preliminary titra-
tion assays from 1 to 50 g/mL. Purified protein derivative
(PPD) of Mycobacterium tuberculosis was used as a positive
control at a concentration of 25 g/mL. All 217 donors were
tested against the 10 TRAP peptide conditions and PPD, ex-
cept for 68 donors who were not tested for reactivity to tp30-
31. Phytohemagglutinin (PHA) was used as an additional
control at a concentration of 10 g/mL in selected assays.
Ex vivo IFN- ELISPOT assay. The IFN- ELISPOT as-
says were carried out using 96-well MAIP ELISPOT plates
(Millipore, Watford, United Kingdom) and human IFN-
ELISPOT kits (Mabtech, Nacka, Sweden) as described in de-
tail elsewhere.11 Briefly, plates were coated with 15 g/mL of
monoclonal antibody to human IFN- (1-D1K; Mabtech),
washed, and blocked with R10 medium (RPMI 1640 medium
with 10% fetal calf serum). The PBMCs, resuspended at a
concentration of 4 × 106/ml in RN5 medium, were applied at
a concentration of 100 L/well (4 × 105 cells/well) and tested
against the 10 TRAP peptide conditions, with PPD and PBS
used as the positive and negative controls, respectively.
TABLE 1
The 14 thrombospondin-related adhesive protein peptides selected for the study*
Epitope aa Sequence Frequency CD4/CD8 Worldwide Africa
tp2 11–30 VIVFLIFFDLFLVNGRDVQN 9% ND Conserved Conserved
tp4 31–50 NIVDEIKYREEVCNDEVDLY 12% ND Variant Variant
tp5 41–60 EVCNDEVDLYLLMDCSGSIR 9% CD4 and CD8 Variant Variant
tp6 51–70 LLMDCSGSIRRHNWVNHAVP 12% CD4 and CD8 Variant Conserved
tp14 131–150 TNLTDALLQVRKHLNDRINR 9% CD4 Variant Conserved
tp23 221–240 ENVKNVIGPFMKAVCVEVEK 7% CD4 Conserved Conserved
tp30 291–310 EPLDVPDEPEDDQPRPRGDN 7% ND Variant Variant
tp31 301–320 DDQPRPRGDNFAVEKPNENI 9% CD4 Variant Variant
tp37 361–380 PPNPPNPPNPDIPEQEPNIP 9% ND Variant Variant
tp38 371–390 DIPEQEPNIPEDSEKEVPSD 9% CD4 Variant Variant
tp40 391–410 VPKNPEDDREENFDIPKKPE 9% ND Variant Conserved
tp43 421–440 NDKSDRYIPYSPLSPKVLDN 5% CD4 Variant Variant
tp47 461–480 SEDRETRPHGRNNENRSYNR 9% CD4 Variant Variant
tp51 526–545 AGLAYKFVVPGAATPYAGEP 14% CD4 Variant Conserved
* aa  amino acid position. Frequency  frequency of responders in a pilot study of 65 adult Kenyans. ND  not determined. Variant sequences are indicated in bold.
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The plates were incubated for 16 hours at 37°C in an at-
mosphere of 5% CO2, washed, and a second biotinylated
monoclonal antibody to IFN- (7-B6-1-Biotin; Mabtech) was
applied at a concentration of 1 g/mL, followed by 1 g/mL
of streptavidin−alkaline phosphatase (Mabtech). Plates were
then washed and developed with alkaline phosphatase conju-
gate substrate kit (Bio-Rad Laboratories, Hercules, CA). The
reaction was stopped after 10−20 minutes by flicking off the
liquid and running the plate under tap water.
Each IFN--producing cell leaves a single spot or footprint
in the ELISPOT assay well. Wells were scored visually, using
a dissection microscope, for the number of purple spots or
spot-forming units (SFUs) per well. The results were ex-
pressed as SFUs/106 PBMCs. The number of responder cells
in the single test well was compared with the background
negative well. A statistical significance table was used that
assumes a Poisson distribution for the number of spots in each
well, and gives a P value for the likelihood that the result is a
true positive rather than a chance event above background.
All responses with a P  0.05 were recorded as positive.
Follow-up for malaria. Active follow-up was performed
weekly by a team of field workers. Each household was vis-
ited, and the temperature of each trial participant was re-
corded. A history was taken regarding fever and any other
clinical symptoms over the preceding week. Those with a his-
tory of fever, or a temperature >37.5°C on the day of the visit,
were referred to the clinic and had duplicate finger prick
blood smears prepared (thick and thin films stained with
Giemsa). Patients presenting with fever to the outpatient
clinic who were parasitemic on the blood film were also in-
cluded in the analysis (passive follow-up). Parasite counts
were scored as parasites/microliter of blood. All data was
double-entered into a computer database and verified using
Fox-pro version 6.0 (Microsoft, Bellevue, WA).
Statistical analyses. The proportion of responders among
adults (15 years old) and children (0−14 years old) were
compared using a Fisher’s exact test, and the magnitude of
responses was compared using Student’s t-test. The endpoints
of the analysis for protection were defined a priori. Analysis
was performed for delay in time to the first parasitemia, and
number of donors with episodes of fever and parasitemia over
two-month and six-month periods following the cross-
sectional ELISPOT assay testing. Since many people living in
malaria-endemic regions have asymptomatic parasitemias, a
second analysis was performed using a cut-off value of
>10,000 parasites/L, which was more likely to detect clini-
cally relevant episodes of parasitemia. Fisher’s exact tests
were used to compare those donors who had TRAP peptide
specific responses with those who did not. Two sample t-tests
were used to compare the SFU values for all 10 TRAP pep-
tide conditions added together (total SFU) for those donors
who subsequently did or did not have an episode. Kaplan-
Meier estimates of the proportion of donors who had had at
least one episode were plotted against time after the cross-
sectional analysis of TRAP ELISPOT assay responses. Log-
rank tests were used to compare survival experience for those
donors with particular TRAP T cell epitope responses to
those without these responses.
The relationship between total SFUs and time to first par-
asitemia appeared to be non-linear; thus, total SFU values
were divided into four categories (<0, 0−49, 50−99, and
100), rather than assessed as a continuous variable. Cox’s
proportional hazards were used to analyze the effect of total
SFUs on time to first episode of malaria. This assumes that
the effect of total SFU category remains constant over time.
RESULTS
Interferon- ELISPOT assay reactivity to TRAP in coastal
Kenyans. Forty-two percent (91 of 217) of the donors re-
sponded to one or more of the 10 TRAP peptide conditions
(14 peptides) (Table 2). This was higher than that observed in
a previous Gambian study where 17% (8 of 48) of the donors
responded to the same 14 peptides, and 32% of donors re-
sponded to 53 overlapping peptides spanning the entire
length of the TRAP antigen.10 Reactivity to nine of the 14
peptides was first described in our study in west Africa,10
whereas the remaining five (tp2, tp30, tp31, tp37, and tp51)
are novel epitopes to which reactivity has never been re-
ported. Magnetic bead depletion studies for 12 responder do-
nors suggested that seven of the 14 peptides (tp14, tp23, tp31,
tp38, tp43, tp47, and tp51) elicited CD4+ T cell responses by
ELISPOT, and two (tp5 and tp6) were either CD4+ or CD8+
T cell mediated (Table 1). Peptides tp5 and tp6 both contain
the known CD8+ T cell epitope tr29 (amino acids 51-59,
LLMDCSGSI).25 and therefore CD8+ T cell reactivity was
probably to this epitope. Almost half (47.9%, 104 of 217) of
the donors were parasitemic at the time of sampling. A sig-
nificantly lower number of parasitemic individuals had a
TABLE 2
Frequency of responders to each of the 10 thrombospondin-related adhesive protein conditions by age group for the 217 donors*
Age
(years) n tp2 tp4–6 tp14 tp23 tp30/1 tp37/8 tp40 tp43 tp47 tp51 PPD
Total
frequency
0–3 47 2 6 1 4 4 2 1 2 2 4 15 20
4.3% 13.0% 2.2% 8.5% 12.9% 4.4% 2.1% 4.4% 4.4% 12.1% 32.6% 42.6%
4–6 46 3 7 5 5 2 6 2 2 3 4 25 20
6.5% 15.2% 10.9% 10.9% 7.1% 13.0% 4.4% 4.4% 6.5% 8.7% 54.3% 43.5%
7–9 49 3 5 1 3 1 1 1 3 1 2 23 16
6.1% 10.2% 1.9% 6.1% 3.3% 1.9% 1.9% 6.1% 1.9% 3.8% 46.9% 32.7%
10–14 33 3 3 1 2 0 1 3 3 2 1 17 12
9.1% 9.1% 3.0% 6.1% 0% 3.0% 9.1% 9.1% 6.1% 3.0% 51.5% 36.4%
15 42 1 13 1 2 4 4 0 2 0 4 16 23
2.4% 31.0% 2.4% 4.8% 11.4% 9.5% 0% 4.8% 0.0% 9.5% 38.1% 54.8%
All 217 12 34 9 16 11 14 7 12 8 15 96 91
5.5% 15.7% 4.2% 7.4% 7.4% 6.5% 3.2% 5.5% 3.7% 6.9% 44.2% 41.9%
* Upper value indicates number of responders: lower value indicates percentage of responders. PPD  purified protein derivative of Mycobacterium bovis.
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TRAP peptide response (34.6%, 36/104) compared with those
without parasitemia (48.7%, 55 of 113) (P = 0.04). The pre-
cursor frequencies for all positive ELISPOT responses
(13/106 PBMCs) ranged from 13 to 100, with a median of
22.5/106 PBMCs, i.e., a median precursor frequency of
1:44,444, with a maximum of 1:10,000 (Table 3). These val-
ues are comparable with those in our previous study in The
Gambia.10
T cell reactivity to CS protein, another major pre-erythro-
cytic vaccine candidate antigen, is focused on several epitope
regions within the carboxy terminus of the antigen.31 Our
previous studies of TRAP ELISPOT responses indicate no
such pattern of immunodominance.10 This is further sup-
ported by the findings in this study where no clear immuno-
dominant peptide region was evident. The high reactivity rate
to pooled peptides tp4-6 (15.7% of donors) is less striking if
one considers the number of peptides in the pool. Thus, the
most frequently recognized individual TRAP peptides were
tp23 (7.4% of donors) and tp51 (6.9% of donors) (Table 2).
Both tp23 and tp51 are conserved among African parasite
strains, and the former is highly conserved worldwide. Both
could therefore elicit cross-strain immunity as components of
malaria vaccine constructs. Forty-four percent (96 of 217) of
the donors responded to PPD, whereas in previous IFN-
ELISPOT studies we have detected rates >70% in malaria-
exposed Gambians.10,11
Similarities in reactivity between adults and children. A
higher proportion of adults (54.8%, 23 of 42) responded to at
least one TRAP condition compared with children (38.9%, 68
of 175), although the difference was not statistically signifi-
cant (P = 0.08). Those individuals less than one year of age
had a low reactivity level of 28.6% (n 7) compared with the
overall average of 42.4% (n  217), with no evidence of a
significant difference (P = 0.73), although numbers were small
in the former group (Figure 1A). The youngest donor to give
an IFN- ELISPOT assay response in this study was two
months of age. Precursor frequencies for the positive re-
sponses were comparable across all age group (adults: median
 20, range  3−73; children: median  22.5, range 
13−100; P = 0.53), and even those individuals less than one
year of age showed a median precursor frequency of 30 SFU/
106 PBMCs, albeit in very few donors (Figure 1B). Selecting
only positive responses introduces a selection bias since only
those responses that reach a certain threshold above back-
ground levels are included (see Materials and Methods).
Thus, the total precursor frequency to all 10 TRAP conditions
(Total SFU) was also analyzed (Figure 1C). There was no
evidence of an increase in total SFU with age (P  0.3).
Indeed, adults and children had comparable median total
SFU values of 53 and 40 SFU/106 PBMCs, respectively, al-
though those individuals less than one year of age did have a
significantly lower value of 10/106 PBMCs (SE  12) com-
pared with all other age groups (P = 0.01) (Figure 1C). Thus,
despite continuous and repeated exposure throughout life,
neither the proportion of responders nor the precursor fre-
quencies for TRAP specific responses increased with age af-
ter the age of one year.
We further analyzed the repertoire of epitope responses by
TABLE 3
Typical interferon- enzyme-linked immunospot values for 20 of the
217 donors recruited to the study
Bg tp2 tp4-6 tp14 tp23 tp30-1 tp37/8 tp40 tp43 tp47 tp51 PPD
3 3 23 5 5 ND 0 8 3 5 10 13
5 3 8 5 3 5 5 5 5 0 0 3
3 3 38 13 13 8 15 3 15 0 10 88
0 8 3 3 8 ND 3 3 5 3 20 10
0 3 0 0 5 3 18 3 0 3 3 0
5 13 15 0 5 8 15 8 15 8 3 25
3 18 3 0 0 10 0 8 3 8 18 33
5 15 10 8 5 13 13 18 3 8 8 18
0 8 23 3 8 5 10 8 10 10 10 38
5 10 58 18 3 5 5 15 10 18 20 35
0 3 0 0 0 0 3 0 3 0 10 23
3 15 15 8 0 3 0 5 3 5 18 20
5 15 30 8 20 13 73 5 18 13 0 23
3 13 8 5 5 15 10 10 5 8 10 115
5 3 10 0 15 13 25 15 5 3 8 70
0 5 5 23 0 10 13 8 3 5 5 20
3 3 13 18 5 ND 13 5 10 15 15 5
0 10 28 10 13 ND 8 0 3 5 10 15
8 18 18 18 28 ND 8 23 8 8 23 10
3 10 20 15 23 10 10 5 15 10 10 13
* Positive responses are indicated in bold. Bg  background value; PPD  purified
protein derivative of Mycobacterium tuberculosis.
FIGURE 1. A, Proportion of responders to thrombospondin-
related adhesive protein (TRAP). An average of 42% of the donors
responded to one or more TRAP peptides, and the numbers of re-
sponders were comparable across all age groups. B, Mean spot-
forming units (SFU) for positive TRAP responses (mean SFU/106
peripheral blood mononuclear cells [PBMC]) were comparable
across all ages. C, Sums of the SFU to all 10 peptide conditions minus
the background value (total SFU/106 PBMC) were variable with age,
with notable decreases at <1 and 9 years of age. Bars show 95%
confidence intervals in A and the mean ± SE in B and C.
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age. Peptide tp4-6 was the most commonly recognized con-
dition in most age groups (Table 2), which is not surprising
given that this is the only condition consisting of three pep-
tides. Thus, for those conditions consisting of more than one
peptide, the responder number was divided by the number of
peptides in the pool, i.e., divided by three for tp4-6 and two
for tp30-31 and tp37-38. Peptides tp23 and tp51 thus emerged
as the most commonly positive peptides in most age groups,
although tp4-6 was the most commonly recognized in adults
(Table 2). Peptide tp30-31 was the least commonly recognized
overall. Thus, the repertoire of ELISPOT assay responses did
not vary dramatically by age in this study.
Lack of an association between naturally induced levels of
IFN- responses to TRAP and protection against malaria.All
donors seen less than 20 times during the first 27 weeks of
follow-up were excluded from the study; thus, 204 (94%) of
the donors were analyzed. The analysis of time to first episode
was censored at eight months, during which time 51% of
donors had one or more episodes of fever and parasitemia
and 28% had one or more episodes of fever and >104 para-
sites/L. Donors who responded to peptides tp14 and tp47
had a significantly decreased time to parasitemia (P = 0.05
and 0.01, respectively). However, this result should be inter-
preted with caution since analysis was univariate, was not
adjusted for the effect of the other tp responses, and multiple
analyses were performed, which increase the chance of a
false-positive result. Indeed, the effect was not apparent when
only donors with >104 parasites/L were considered. Each of
the 10 TRAP conditions were analyzed individually for an
association with protection against the subsequent develop-
ment of parasitemia, and there was no evidence that any pro-
tected against the development of fever and parasitemia (any
or >104/L) over the ensuing two months (10 weeks) or six
months (27 weeks).
Those who responded in the IFN- ELISPOT assay to one
or more of the TRAP peptide conditions were compared with
those who failed to respond. The TRAP peptide responders
were not significantly protected against subsequent episodes
of fever together with parasitemia (any and >104/L over a
two- and six-month period) compared with the non-
responders. Maentel-Haenzel tests for homogeneity sug-
gested that there was no evidence for significantly different
effects of tp responses on the likelihood of a subsequent epi-
sode between the different age categories (Table 4). The
TRAP responders did not seem to progress more slowly to
parasitemia (any or >104/L) than non-responders (Figure 2),
and this was further confirmed by log-rank analysis (P values
 0.28–0.89).
The responses to all 10 ELISPOT conditions were added
together after subtracting the background value to derive a
total precursor frequency to all 14 TRAP peptides and de-
noted the total SFU. Total SFU values were normally distrib-
uted with a mean value of 45/106 PBMCs and a standard
deviation of 67.6 / 106 PBMCs (Figure 3A), a negative value
being derived when the background response was greater
than the peptide-specific responses. Thus, the maximum pre-
cursor frequency to the 14 peptides tested in this study was
255 specific cells/106 PBMCs or one in every 4,000 PBMCs. A
plot of total SFU by age as a continuous variable did not show
any clear association. We hypothesized that those donors with
higher total SFU values might be protected against episodes
of fever and parasitemia. However there was no significant
difference in total SFU values between those donors who
developed fever and parasitemia and those who did not over
a two-month (P = 0.11) or six-month period (P = 0.57) (Table
5). Further analysis for fever with a parasitemia >104/L
failed to show a significant effect over two (P = 0.78) and six
months (P = 0.69) of follow-up (Table 5). Adjustments for age
did not affect the results of this analysis.
Total SFU values were divided into four groups for further
analysis: <0, 0−49, 50−99, and 100. The proportion who
have had at least one episode was estimated by time for each
group for episodes of fever and any parasitemia or a parasit-
emia >104/L) (Figure 3B and C). The effect of total SFU
category was estimated, adjusting for age, using Cox’s pro-
portional hazards. There was no evidence of a protective ef-
fect of total SFU (any parasitemia, P = 0.32; parasitaemia
<104/L, P = 0.26).
Complete change in ELISPOT assay reactivity after one
year.Adults and children showed similar reactivity in this
study, suggesting that ex vivo ELISPOT assay responses
might reflect recent exposure rather than long-term malaria
experience. To assess whether ELISPOT assay reactivity
changes over time, we retested 69 of the original 217 donors
after one year in identical IFN- ELISPOT assays using ex-
actly the same assay conditions. The response rate in the
retested donors was 36.2% (25 of 69), which was much lower
than the response rate of 69.6% (48 of 69) the previous year.
This may be due to selection bias since the retested donors
were specifically selected because they responded in 1998.
Indeed, the overall response rate in that year was 41.9% (91
of 217) for all donors tested, and thus comparable to the 1999
value of 36.8% (P = 0.48). The PPD reactivity rates were low
in 1998 (40.6%) and 1999 (46.4%), suggesting an overall low
PPD reactivity in this population. The reason for this is not
known. A PHA-positive control was included in the 1999
analysis and 100% of the donors gave a positive PHA re-
sponse, indicating that a problem with the assay itself was not
responsible for low reactivity. The precursor frequency values
for 1998 and 1999 could not be compared because the back-
ground values were significantly higher on retesting in 1999.
Somewhat surprisingly, responses had entirely changed
TABLE 4
Analysis of those donors who had a thrombospondin-related adhesive protein peptide (tp) response compared to those who had none*
With a tp response Without a tp response
Pn Frequency % n Frequency %
Any parasitemia in 2 months 57 13 23 81 8 10 0.05
Parasitemia >104/L in 2 months 57 5 9 81 4 5 0.49
Any parasitemia in 6 months 57 23 40 81 30 37 0.73
Parasitemia >104/L in 6 months 57 14 25 81 15 19 0.40
* Frequency  number of donors with at least one episode. The P value in bold is statistically significant.
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over the one-year period, with only four (5.3%) of the origi-
nal 75 positive responses still present in 1999 (Table 6). There
was no evidence of an association between those donors who
responded to one or more TRAP condition in 1998 and those
who responded in 1999 (P = 0.19). Our data suggests that
malaria-specific reactivity detected by IFN- ELISPOT assay
is not long lasting in a malaria-exposed population, and may
provide one explanation why the IFN- ELISPOT assay re-
sponses failed to correlate with protection in this study.
The reactivity pattern to the 10 peptide conditions com-
pletely changed over the year in these 69 donors. Peptide tp23
was the most frequently recognized epitope on testing in 1998
(14 of 69 donors, 20.3%) followed by tp51 (10 of 69 donors,
14.5%). However, one year later tp2 was most commonly
recognized (9 of 69 donors, 13%), followed by tp40 and tp47
(5 of 69 donors, 7.2%). Both tp23 and tp2 fall within highly
conserved regions of TRAP, suggesting a recognition bias for
conserved epitopes. Indeed, the second most commonly rec-
ognized peptides (tp51 and tp40) are conserved in Africa, and
tp47 has one polymorphic residue, but is conserved across
almost all known strains of TRAP.32 A recognition bias for
conserved regions of key parasite antigens obviates the host
problems associated with antigenic polymorphism.
DISCUSSION
Residents of malaria-endemic regions acquire partial resis-
tance to malaria infection, thus providing the rationale for
studies of immunologic correlates of protection. Field studies
assessing for protective T cell responses in malaria-exposed
populations have generally used lymphoproliferation assays
and assayed cytokine release by ELISA.1−6 The ELISPOT
assay has been used to accurately determine malaria-specific
CD4+ and CD8+ T cell precursor frequencies in naturally
exposed and vaccinated individuals.10,11,13,16,33−35 However,
no studies have addressed whether ELISPOT assay responses
provide a surrogate of protective immunity. In the present
study, we assessed 217 Kenyans by ELISPOT assay for rapid
IFN- release to 14 peptides spanning 42% of the malaria
vaccine candidate antigen P. falciparum TRAP. Almost half
(42%) of the donors responded to one or more peptides,
which included five novel epitopes, two of which are con-
served in Africa.
Malaria mortality is mainly restricted to children in ma-
laria-endemic regions. Thus, detailed comparison of reactivity
between age groups provides useful information regarding
the prevalence of ELISPOT assay responses throughout life.
The proportion of TRAP-specific responders was comparable
between children and adults, as were precursor frequency
levels and the repertoire or responses. This contrasts with the
findings of other investigators, who showed that malaria-
specific IFN- reactivity increases with age,34,36−38 albeit to
other antigens. These latter studies assessed IFN- reactivity
by ELISA of cultured PBMCs. However, we know from pre-
vious studies that cultured cells do not give the same IFN-
ELISPOT assay reactivity as freshly isolated PBMCs.11 Re-
sponses were found from two months of age, which is the
youngest age that malaria-specific ELISPOT assay responses
have been shown.
Donors were followed up weekly for one year for the de-
velopment of fever and parasitemia and analyzed for protec-
tive correlates with the IFN- ELISPOT assay responses.
This is the first study to assess for protective correlates with
naturally induced T cell responses determined by ELISPOT
assay, and also the first study of the protective efficacy of T
cell responses to TRAP. A comprehensive analysis of time to
first parasitemia and episodes of parasitemia two and six
months after testing with the ELISPOT assay failed to show
evidence of a protective association for any of the individual
TRAP peptides. Indeed, having an IFN- ELISPOT assay
response to one or more of the TRAP peptides did not confer
a protective advantage compared with the non-responders in
this study. There was also no evidence of a protective effect
for those donors with higher total precursor frequency levels
to all 14 TRAP peptides (total SFU).
The presence of reactivity to multiple T cell determinants
within TRAP in naturally exposed donors,10,25–27 and the piv-
otal role that TRAP and ex vivo IFN- have shown in liver-
stage protective immunity in laboratory-based studies,7–9 sug-
gested that high level T cell responses to TRAP would protect
in studies of natural immunity. The lack of any evidence of a
protective response using the predetermined endpoints (time
FIGURE 2. Kaplan-Meier plots of the proportion of donors having at least one episode by time for those donors who responded to one or more
thrombospondin-related adhesive protein peptides (tps) (Any tp) compared with those who did not (No tp). Having a tp response failed to provide
a significant survival advantage for the subsequent development of A, any parasitemia or B, a parasitemia >104/L.
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to first episode of fever and parasitemia, development of par-
asitemia at different thresholds, and testing of conserved and
variable epitope regions containing both CD4 and CD8 T cell
epitopes) therefore deserves detailed consideration. The
power of this study was determined retrospectively, since it
was unknown at the onset how many donors would respond
or the magnitude of the differences between groups. The best
power achieved was >46% for the any tp response versus no
response analysis to detect a difference of 23% and 10% as
significant. Increasing the number of donors would have in-
TABLE 5
Total spot-forming unit values and protection against malaria
One or more episodes No episodes
Pn Mean SE n Mean SE
Any parasitemia in 2 months 43 60.5 12.3 161 41.8 5.0 0.11
Parasitemia >104/L in 2 months 19 49.9 20.6 185 45.3 4.8 0.78
Any parasitemia in 6 months 92 48.7 8.0 112 43.3 5.6 0.57
Parasitemia >104/L in 6 months 51 49.0 11.1 153 44.7 5.1 0.69
FIGURE 3. Sum of the enzyme-linked immunospot values to all 10 peptide conditions calculated for each donor (total spot-forming units
[SFU]). A, The total SFU distribution for all 217 donors recruited into the study was normally distributed. Donors were separated into four
categories according to their total SFU values (<0, 0−49, 50−99, and 100). Kaplan-Meier estimates of the four groups demonstrated that there
was no significant survival advantage for donors with a high total SFU value and the subsequent development of an episode of fever and B, any
parasitemia or C, a parasitemia >104/L.
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creased the power of this study. However, it was notable that
none of the parameters analyzed suggested a protective ef-
fect.
The ex vivo IFN- ELISPOT assay is frequently used to
assess for T cell responses in studies of malaria vaccine effi-
cacy in humans.16,35 It is therefore important to test whether
IFN- ELISPOT assay responses measured in field studies
are indeed protective. The only study linking IFN- responses
in naturally exposed individuals with protection against ma-
laria infection used PBMCs cultured for six days with pep-
tides derived from the liver stage antigen-1, i.e., a cultured
rather than an ex vivo assay.5 Freshly isolated ex vivo PBMCs
do not respond to the same malaria peptides in the IFN-
ELISPOT assay as PBMCs cultured for 14 days in peptides,
suggesting that the two methods detect different T cell sub-
sets.11 Thus, the ELISPOT assay of cultured cells may detect
protective T cells not apparent in the ex vivo assay. It is not
clear how long IFN- ELISPOT assay responses are main-
tained in naturally exposed donors, but in an RTS,S vaccine
trial malaria, specific T cell responses measured by an ex vivo
ELISPOT assay waned after one month.39 The temporal
variation of malaria-specific ELISPOT assay responses have
yet to be assessed in the field, but might be predicted to alter
according to seasonality as observed with other measures of T
cell function.40−42 In the present study, repeat testing after
one year for selected donors demonstrated completely
changed reactivities for all donors, suggesting that responses
do not persist long-term and might reflect recent malaria ex-
posure. Indeed, the parasitemic donors in 1998 were more
likely to be TRAP non-responders than aparasitemic. Thus,
ongoing malaria infection at the time of testing may suppress
malaria-specific ELISPOT assay reactivity, a phenomenon
well described for malaria-specific lymphoproliferative re-
sponses.43−45 We did not allow for an absence of parasitemia
at the time of testing in the analysis for this study.
It is possible that T cell responses to TRAP are not pro-
tective. One would think that this unlikely given the role of
TRAP in sporozoite motility20 and hepatocyte invasion.21
Moreover, TRAP homologues have repeatedly been shown
to be protective in animal models,14,22−24 although the
ELISPOT assay reactivity for a single epitope reached 1,000
specific cells/106 splenocytes in protected animals in the latter
study.24 In our study, the maximum precursor frequency to all
14 epitopes was 255/106 PBMCs (median  43/106 PBMCs)
or one in 4,000. However, we do not know how numbers of
specific splenic cells correlate with specific PBMCs. Most of
the peptides used in this study elicited CD4+ T cell responses,
and only peptide pool tp4-6 contained proven CD8+ T cell
epitopes. TRAP-specific CD8+ T cells and/or antibodies may
be protective in this population, rather than CD4+ T cells.
Certainly, field studies suggest that antibodies to TRAP play
a protective role,28,29 but no studies have previously directly
addressed the role of TRAP-specific T cells in naturally in-
duced protection. Several studies have correlated protection
with interleulin-4 (IL-4) or IL-10 release in response to vari-
ous vaccine candidate antigens,3,4 and the profile of other
cytokines induced by TRAP may have influenced our results.
Indeed, in a separate study, we found high levels of IL-10
TABLE 6
Representative results for 20 of the 69 donors re-tested in 1999*
* Filled or hatched boxes indicate a positive response.
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reactivity to the same TRAP-derived peptides in coastal Ken-
yans (Flanagan KL and others, unpublished data).
This study provides evidence that the levels of epitope-
specific T cell responses (median  23/106 PBMCs) in indi-
viduals with significant natural exposure to malaria do not
afford detectable protection against malaria infection. This is
consistent with studies of animal models of malaria that indi-
cate that immune responses approximately an order of mag-
nitude higher than this are required to induce protection
against sporozoite challenge. Thus, it is likely that similarly
high levels of T cell response will need to be induced by
subunit vaccination in humans to afford useful protection.
Recent data from Phase I/IIa studies of heterologous prime-
boost immunization with DNA and modified virus Ankara
(MVA) vaccines encoding TRAP are consistent with this in-
terpretation (McConkey SJ and others, unpublished data).
Studies for protective T cell responses in malaria-endemic
regions are crucial to the development of effective malaria
vaccines. This comprehensive study of more than 200 natu-
rally exposed donors provides useful information regarding
ELISPOT assay reactivity in naturally exposed populations,
and provides baseline data for ongoing field efficacy trials of
TRAP-based candidate vaccines.
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